Published in Healthcare Finance, Tax and Law Weekly, January 31st, 2007
During the 3-month period ended September 30, 2006, the company achieved the following steps in preparation for the upcoming multicenter trial for Neuradiab and its subsequent planned commercialization:
1) Recruited Alan M. Ezrin, PhD, to join the company as chief operating officer.
2) Submitted a request to the U.S. Food and Drug Administration (FDA) for an end of phase II meeting on Neuradiab.
3) Submitted an E.U....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly